Drug Trial Radar · NCT07436234
A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
111
Planned (sponsor's estimate)
Start
Mar 2, 2026
Primary completion
Sep 30, 2026
Study completion May 13, 2027
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Feb 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK139 in the treatment of participants with moderate to severe SAR
Conditions
- Seasonal Allergic Rhinitis
Interventions
AK139Drug
AK139 regimen 1- subcutaneous injection.
AK139Drug
AK139 regimen 2- subcutaneous injection
PlaceboDrug
Placebo-subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in daily reflective total nasal symptom scores (rTNSS) over 2 weeks of treatmentTime frame: Up to week 2
- Incidence of adverse events (AEs)Time frame: Up to week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tong-Ren hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.